therapeutic vaccine News
-
ImmunAdd team wins 18th National Award in the Academic Research
Our team was awarded the 18th National Award in the Academic Research for “the Discovery of IA05 as a Novel Saponin Adjuvant for Therapeutic ...
-
The First-in-Human Phase 1b Safety Clinical Trial of CuraVac’s Potential Myasthenia Gravis Therapeutic Vaccine Succesfully Meets its Safety Primary End Points.
General information: First-in-human clinical trial (phase 1b, I/II) testing the potential MG therapeutic vaccine, CV-MG01, against a placebo in patients with Myasthenia Gravis conducted at Antwerp University Hospital (UZA) in Belgium. The study consisted in 10 visits over 20 weeks (Part A) and is followed by a 2-year long term follow-up period (Part B-ongoing). Three cohorts of 8 patients were ...
-
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of viral load HOOKIPA Pharma Inc. (NASDAQ: HOOK, ...
-
Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
TG4050 (myvac): First positive results from the two Phase I trials. Additional data to be presented at AACR 2022 in April. TG4001: First patient enrolled in Phase II study in June 2021. Active patient recruitment in Europe and trial initiation in the US. Interim analysis expected in Q4 2022. BT-001 (Invir.IO™): IND approval for Phase I/IIa trial in the US, ongoing enrollment in Europe. ...
By Transgene
-
Enterome to present promising clinical progress on its OncoMimics™ pipeline and Mimicry Platform at Jefferies Healthcare Conference
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that its CEO, Pierre Belichard, will provide a company update (in person) at the Jefferies Healthcare Conference in New York City, US which will take place June 8-10, 2022. In his presentation, Dr. Belichard will provide an ...
By Enterome
-
Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT. A live webcast of the presentation can be accessed through the ...
-
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a ...
-
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ET. A live webcast of the presentation can be ...
-
Vaxcyte to Present at the Jefferies Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 8:30 a.m. ET / 5:30 a.m. PT. A live webcast of the ...
-
NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio with Three New Antigens via Series of Rights Acquisitions
GRAND FORKS, ND – June 10, 2014 – NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’s Candida vaccine pipeline. These three antigens are in addition to the ...
-
Calviri Named Most Fundable Company by Pepperdine Graziadio Business School
Calviri, a biotechnology company developing unique products against cancer, is pleased to announce that it was awarded one of three Platinum awards in the Pepperdine Graziadio Business School’s third annual Most Fundable Companies® List. Calviri competed against more than 4,500 early-stage startups from all 50 US states for this top designation. A total of 20 companies, all with less ...
By Calviri
-
Vaxcyte to Participate in Upcoming Investor Conferences in May
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: BofA Securities 2022 Healthcare Conference May 10-13, 2022; Las Vegas, NV Fireside chat will ...
-
Biosceptre Joins European Cooperation in Science & Technology COST Group BMBS 1406 – with focus on Ion Channels and Immune Response
Biosceptre announces today its membership of the COST Group (European Cooperation in Science & Technology) project COST BMBS 1406. This project, established in 2014, created the Ion chan-Immune response network that brings together internationally recognised scientists and companies across 15 European countries with the common goal of understanding the function of ion channels in Bimmune ...
-
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida. Please see ...
-
Vitruvian BioMedical Licenses New Alzheimer’s Vaccine Targeting ABeta + TAU
VITRUVIAN BioMedical, Inc. (“VITRUVIAN”), a biotechnology company, today announced obtaining the Exclusive License for a new Therapeutic Vaccine for Alzheimer’s Disease (AD) from Dr. Yoh Matsumoto from the Immunotherapy Development Inc. in Saitama, Japan and the Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. The AD Vaccine, YM7555, is a DNA Vaccine that targets ...
-
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. Management will then host a webcast and conference call at ...
-
Update on Continued Research in Oncology
Abera Bioscience AB (“Company” or “Abera”) initiated research and development in immuno-oncology in 2021 with a first sub-goal to explore the potential of the company’s platform in the area and to carry out initial studies for further prioritization. In accordance with the press release regarding a private placement sent out December 23rd, in which Abera informed ...
-
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to ...
-
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022. Please see ...
-
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
TG4050 induced robust anti-tumor cellular immune responses against multiple neoantigen targets in all evaluable patients (4/4). TG4050 monotherapy was also associated with the first signs of clinical activity. TG4050 was well tolerated, with no related Serious Adverse Events reported across the two studies to date. Additional patients are being enrolled, with the aim to treat up to 43 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you